Buchumschlag

Loss of β‐cell identity in human islets treated with glibenclamide

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Claudia Fernández, Montserrat Nacher, Kevin Rivera, Sandra Marín‐Cañas, Maria Sorribas, Gabriel Moreno‐González, Elisabet Estil·les, Patricia San José, Noèlia Téllez, Eduard Montanya
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Diabetes, Obesity and Metabolism
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

The role of gut–islet axis in pancreatic islet function and glucose homeostasis
von: Qi Chen, et al.
Veröffentlicht: (2025)

Boosting the engraftment of subcutaneously transplanted pancreatic islets by nanofat
von: Selina Wrublewsky, et al.
Veröffentlicht: (2025)

The selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta‐cell mass and function in vitro
von: Klaudia Toczyska, et al.
Veröffentlicht: (2024)

Development and validation of a novel method for evaluation of multiple islet autoantibodies in dried blood spot using dissociation‐enhanced lanthanide fluorescent immunoassays technology, specific and suitable for paediatric screening programmes
von: Beatrice Dufrusine, et al.
Veröffentlicht: (2024)

Deletion of RalGAP β protects pancreatic β cells and improves glycemic control
von: Weikuan Feng, et al.
Veröffentlicht: (2025)

Tirzepatide in the NHS : The known unknowns of treating obesity at a national scale
von: Ashley Kieran Clift, et al.
Veröffentlicht: (2025)

Pancreatic β‐cell turnover in health and disease
von: Yasmine Alcibahy, et al.
Veröffentlicht: (2025)

The daunting task of recruiting insulin‐treated patients living with type 2 diabetes mellitus for intensive lifestyle interventions
von: Cathy J. Sun, et al.
Veröffentlicht: (2024)

Research advances in understanding crosstalk between organs and pancreatic β‐cell dysfunction
von: Peng Huang, et al.
Veröffentlicht: (2024)

GLP ‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations
von: Teerapon Dhippayom, et al.
Veröffentlicht: (2025)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
von: Irl B. Hirsch, et al.
Veröffentlicht: (2024)

If treating obesity with GLP ‐1‐based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials
von: Anastasios Tentolouris, et al.
Veröffentlicht: (2026)

Using natriuretic peptides to screen for, identify and treat stage B heart failure in people with type 2 diabetes: An initial cost‐effectiveness analysis
von: William B. Horton, et al.
Veröffentlicht: (2024)

Importance of targeting post‐prandial hyperglycaemia to achieve HbA1c goals in insulin glargine‐treated subphenotypes of type 2 diabetes
von: Wolfgang Landgraf, et al.
Veröffentlicht: (2025)

Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide
von: Rodolfo J. Galindo, et al.
Veröffentlicht: (2025)

The impact of novel probiotics isolated from the human gut on the gut microbiota and health
von: Robert Caesar
Veröffentlicht: (2024)

Interpreting Lean Mass Changes During Tirzepatide‐Induced Weight Loss: Beyond Quantitative Metrics
von: Tuba Uyanık
Veröffentlicht: (2026)

Correction to “Efficacy and safety in tirzepatide‐treated Korean adults with type 2 diabetes—A post hoc analysis of SURPASS‐AP‐combo and SURPASS‐3”
Veröffentlicht: (2026)

Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT ‐ CN trial
von: Lin Zhao, et al.
Veröffentlicht: (2025)

Efficacy and safety of continuous glucose monitoring on glycaemic control in patients with chronic pancreatitis and insulin‐treated diabetes: A randomised, open‐label, crossover trial
von: Line Davidsen, et al.
Veröffentlicht: (2025)

Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
von: Stergios A. Polyzos, et al.
Veröffentlicht: (2024)

Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability
von: Gian Paolo Fadini, et al.
Veröffentlicht: (2026)

The effect of altered sleep timing on glycaemic outcomes: Systematic review of human intervention studies
von: Romy Slebe, et al.
Veröffentlicht: (2024)

Real‐world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide ( SEMA ‐elderly)
von: Vincenzo Fiore, et al.
Veröffentlicht: (2025)

GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
von: Jirawan Vienghirun, et al.
Veröffentlicht: (2026)

Long‐term delirium and survival outcomes in patients treated with GLP ‐1 receptor agonists versus metformin in type 2 diabetes: A population‐based cohort study
von: Mingyang Sun, et al.
Veröffentlicht: (2025)

Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials
von: Ronnie Aronson, et al.
Veröffentlicht: (2025)

Impact of intermittent fasting on self‐regulatory behaviour and sleep in participants with insulin‐treated type 2 diabetes: A secondary analysis of the INTERFAST‐2 randomised controlled trial
von: Anna Ramirez‐Obermayer, et al.
Veröffentlicht: (2026)

Real‐world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide
von: Caroline Swift, et al.
Veröffentlicht: (2024)

Gene Therapy and Gene Editing in Type 1 Diabetes: CRISPR ‐Based β‐Cell Replacement and Treg Immune Modulation Approaches
von: Tzu‐Min Lin, et al.
Veröffentlicht: (2026)

Relation of the stress hyperglycaemia ratio to residual risk in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia AF Project III cohort
von: Eva Soler‐Espejo, et al.
Veröffentlicht: (2025)

Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network
von: Abigail Postema, et al.
Veröffentlicht: (2025)

Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta‐analysis with focus on an Asian subpopulation
von: Myung Jin Kim, et al.
Veröffentlicht: (2025)

Pioglitazone reduces serum ketone bodies in sodium‐glucose cotransporter ‐2 inhibitor‐treated non‐obese type 2 diabetes: A single‐centre, randomized, crossover trial
von: Min Yang, et al.
Veröffentlicht: (2024)

Is low‐dose glucagon needed and effective in preventing fasted exercise‐induced hypoglycaemia in type 1 diabetes treated with the MiniMed 780G , an automated insulin delivery system?
von: Sissel Banner Lundemose, et al.
Veröffentlicht: (2024)

Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care – The countrywide cross‐sectional AUSTRO ‐ PROFIT study
von: Harald Sourij, et al.
Veröffentlicht: (2024)

A comparative study of the effects of imeglimin add‐on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low‐dose metformin ( MEGMI‐CGM study)
von: Akihiro Takahashi, et al.
Veröffentlicht: (2024)

Adipocyte‐specific IGF1R knockout activates the β‐catenin/apelin axis to combat diet‐induced obesity in male mice
von: Haoan Wang, et al.
Veröffentlicht: (2025)

Differential associations of risk factors with severe and non‐severe hypoglycaemia: the Hypoglycaemia Assessment Tool prospective observational study in people with insulin‐treated type 1 diabetes and type 2 diabetes
von: Ying He, et al.
Veröffentlicht: (2024)

Effect of introduction of intermittently scanned continuous glucose monitoring on glycaemic control in individuals living with type 2 diabetes mellitus treated with non‐insulin therapies—A randomised controlled trial
von: Emmanuel Ssemmondo, et al.
Veröffentlicht: (2024)